Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.
Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, Valvano MR, Calvaruso V, Gioffreda D, Milella M, Morisco F, Felder M, Brancaccio G, Fasano M, Gatti P, Tundo P, Barone M, Cozzolongo R, Angelico M, D'Andrea G, Andriulli N, Abate ML, Mazzella G, Gaeta GB, Craxi A, Santantonio T. Andriulli A, et al. Among authors: morisco f. J Hepatol. 2014 Jan;60(1):16-21. doi: 10.1016/j.jhep.2013.07.040. Epub 2013 Aug 20. J Hepatol. 2014. PMID: 23973930 Free article.
Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C.
Ascione A, De Luca M, Di Costanzo GG, Picciotto FP, Lanza AG, Canestrini C, Morisco F, Tuccillo C, Caporaso N. Ascione A, et al. Among authors: morisco f. Curr Pharm Des. 2002;8(11):977-80. doi: 10.2174/1381612024607018. Curr Pharm Des. 2002. PMID: 11945144 Clinical Trial.
The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, Tuccillo C, Sorvillo F, Caporaso N, Amato G. Carella C, et al. Among authors: morisco f. Eur J Endocrinol. 2002 Jun;146(6):743-9. doi: 10.1530/eje.0.1460743. Eur J Endocrinol. 2002. PMID: 12039693
Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study.
Mazziotti G, Sorvillo F, Stornaiuolo G, Rotondi M, Morisco F, Ruberto M, Cioffi M, Amato G, Caporaso N, Gaeta GB, Carella C. Mazziotti G, et al. Among authors: morisco f. J Endocrinol Invest. 2002 Jul-Aug;25(7):624-30. doi: 10.1007/BF03345087. J Endocrinol Invest. 2002. PMID: 12150338
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.
Cammà C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AG, Mangia A, Andriulli A, Puoti M, Spadaro A, Freni M, Di Marco V, Cino L, Saracco G, Chiesa A, Crosignani A, Caporaso N, Morisco F, Rumi MG, Craxì A. Cammà C, et al. Among authors: morisco f. Gut. 2002 Dec;51(6):864-9. doi: 10.1136/gut.51.6.864. Gut. 2002. PMID: 12427791 Free PMC article.
Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.
Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta GB, Caporaso N, Carella C. Mazziotti G, et al. Among authors: morisco f. Cancer. 2002 Dec 15;95(12):2539-45. doi: 10.1002/cncr.11002. Cancer. 2002. PMID: 12467068 Free article.
253 results